Putting ACCOMPLISH into context: management of hypertension in 2010

McAlister, Finlay A.; Herman, Robert J.; Khan, Nadia A.; Rabkin, Simon W.; Campbell, Norm
October 2010
CMAJ: Canadian Medical Association Journal;10/19/2010, Vol. 182 Issue 15, p1600
Academic Journal
In this article the authors look at the implications of Avoid Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial for clinicians in Canada. They explain that trial evaluated whether combination with a dihydropyridine calcium channel blocker and an angiotensin-converting enzyme (ACE) inhibitor was wore effective. They suggest that there was a benefit with the combination of calcium channel blocker and ACE inhibitor in terms of death.


Related Articles

  • Newer BP Drugs Might Not Be Better. Frei, Rosemary // Renal & Urology News;Apr2012, Vol. 11 Issue 4, p30 

    The article reports on a follow-up study on the effect of calcium channel blockers (CCBs) and angiotensin converting enzyme (ACE) inhibitors in lowering cardiovascular (CV) deaths in patients with hypertension. It states that the study shows that CCBs and ACE may be no better than diuretics and...

  • Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients. Eguchi, K; Kario, K; Shimada, K // Journal of Human Hypertension;Sep2001, Vol. 15 Issue 9, p643 

    In a prospective randomised cross-over study, we compared the effects of ACE inhibitor temocapril and calcium channel blocker (CCB) amlodipine on ambulatory blood pressure in 59 asymptomatic elderly hypertensive patients (mean age 69 years). This study was performed in a cross-over fashion after...

  • Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. Brewster, Lizzy M.; Seedat, Yackoob K. // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    Background: Clinicians are encouraged to take an individualized approach when treating hypertension in patients of African ancestry, but little is known about why the individual patient may respond well to calcium blockers and diuretics, but generally has an attenuated response to drugs...

  • Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists. López-Jaramillo, P; Casas, J P // Journal of Human Hypertension;Mar2002 Supplement, Vol. 16 Issue 3, pS34 

    The endothelium plays a crucial role in the pathogenesis of cardiovascular disease. Endothelial function is attenuated by the presence of different well known cardiovascular risk factors. Evaluation of endothelial vaso-dilator function serve as an index integrating the overall stress imposed by...

  • Choice of First Antihypertensive: Simple as ABCD? Mahmud, Azra; Feely, John // American Journal of Hypertension;Aug2007, Vol. 20 Issue 8, p923 

    Background: The AB/CD British Hypertension Society guidelines predict that the blood-pressure response to antihypertensive agents A (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers) or B (beta blockers) drugs is better in those aged <55 years, whereas that to agents C...

  • 390. Combination antihypertensives slows progression of renal disease. Herlitz, H.; Harris, K.; Risler, T. // Kidney;May/Jun2002, Vol. 11 Issue 3, p130 

    Discusses a study which examined the effects of an angiotensin-converting enzyme inhibitor and a calcium antagonist on the progression of renal disease. Methodology; Results; Conclusion.

  • Once-daily combination ACE inhibitor/calcium antagonist for hypertension.  // Modern Medicine;Mar97, Vol. 65 Issue 3, p38 

    Reports that the fixed combination of the angiotensin-converting enzyme (ACE) inhibitor enalapril maleate and the calcium antagonist felodipine ER called Lexxel has been cleared by the US Food and Drug Administration (FDA) for marketing. Drug indication; Dosage and contents; Side effects.

  • Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: a pilot study of prescription-event monitoring in Japan. Samizo, K.; Kawabe, E.; Hinotsu, S.; Sato, T.; Kageyama, S.; Hamada, C.; Ohashi, Y.; Kubota, K.; Samizo, Kazuo; Kawabe, Eri; Hinotsu, Shiro; Sato, Tsugumichi; Kageyama, Shigeru; Hamada, Chikuma; Ohashi, Yasuo; Kubota, Kiyoshi // Drug Safety;Aug2002, Vol. 25 Issue 11, p811 

    Introduction: Two pilot studies for prescription-event monitoring in Japan (J-PEM) were launched in 1997 and 1998. Here we present data regarding adverse events that were reported in the second pilot J-PEM study where losartan was compared with ACE inhibitors and dihydropyridine...

  • First-Line Treatment for Hypertension. QUYNH BUI // American Family Physician;6/1/2010, Vol. 81 Issue 11, p1333 

    The article examines the case of a 53-year-old healthy woman with persistent hypertension. It compares the effects of thiazide diuretics, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCBs) with placebo. It was found that thiazide diuretics and ACE...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics